Background: This study focused on the association between preoperative serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (Cyfra 21-1) levels and pathologic parameters in patients with resected non-small-cell lung cancer (NSCLC). Materials and Methods: The records of 527 patients who underwent pulmonary resection of NSCLC were reviewed. The association between preoperative serum CEA and Cyfra 21-1 levels and variables that had p-values of less than 0.05 in a t-test or one-way analyses of variance was analyzed by multiple linear regression. Results: The mean serum CEA and Cyfra 21-1 levels prior to surgery were 6.8±23.1 mg/dL (range, 0.01 to 390.8 mg/dL) and 5.4±12.3 mg/dL (range, 0.65 to 140.2 mg/dL). The serum CEA levels were associated with tumor (T) and lymph node (N) stage and histology. The serum Cyfra 21-1 levels were associated with T stage, tumor size, and histology. Multiple linear regression indicated that serum CEA levels were associated with T (T3/4 vs. T1: β=8.463, p=0.010) and N stage (N2/3 vs. N0: β=9.208, p＜0.001) and histology (adenocarcinoma vs. squamous cell: β=6.838, p=0.001), and serum Cyfra 21-1 levels were associated with tumor size (β=2.579, p ＜0.001) and histology (squamous cell vs. adenocarcinoma: β=4.420, p=0.020). Conclusion: Serum CEA level was correlated with T and N stage, and Cyfra 21-1 with tumor size. CEA and Cyfra 21-1 showed histologic correlation. CEA is mainly elevated in adenocarcinoma and Cyfra 21-1 in squamous cell carcinoma. These results might be helpful for predicting pathologic status in preoperative NSCLC.
INTRODUCTION
Carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (Cyfra 21-1) are the most commonly investigated tumor markers in non-small-cell lung cancer (NSCLC). They have been investigated for the purpose of early detection, prognosis stratification, treatment monitoring and selection, and recurrence monitoring. In NSCLC, adjuvant platinum-based chemotherapy is considered the standard treatment for stage II and III. A potential benefit of adjuvant chemotherapy for stage Ib has not yet been determined. Therefore, a current challenge in NSCLC is to identify patients that might benefit from adjuvant treatment [1, 2] . Several studies have suggested that CEA and Cyfra 21-1 were independent − 193 − prognostic factors and good tools for choosing candidates for adjuvant chemotherapy [3] [4] [5] [6] [7] [8] [9] [10] . However, contrasting recommendations have also been reported [11] [12] [13] . We postulated that CEA and Cyfra 21-1, which seem to be associated with patient prognosis, might be related to pathologic factors. This study focused on the association between preoperative serum CEA and Cyfra 21-1 levels and pathologic parameters in relation to prognosis in patients with resected NSCLC.
MATERIALS AND METHODS

1) Patients
The records of 982 patients who underwent pulmonary re- The institutional review board (IRB) of the Yonsei University College of Medicine approved this retrospective study.
The need for subsequent individual consent of patients whose records were evaluated was waived because individuals were not identified in this study.
2) CEA and Cyfra21-1 measurement
Blood samples were obtained by peripheral venous puncture on admission to the unit prior to any staging or resection. Serum CEA or Cyfra 21-1 levels were measured as part of routine clinical examination. CEA was assessed by UniCel DxI 800 Immunoassay (Beckman Coulter, Brea, CA, USA), and Cyfra 21-1 by Elecsys 2010 system (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions. Serum levels ＜5.0 ng/mL were defined as normal for CEA and ＜3.3 ng/mL for Cyfra21-1.
3) Statistical analysis
Statistical analysis was performed using SPSS ver. 13 (Table 2 ).
DISCUSSION
The serum CEA level was correlated with T and N stage. and CEA was suggested as a prognostic factor in NSCLC
